Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer Despite ...

Artificial intelligence (AI) has the potential to transform HNSCC care by addressing critical challenges in diagnostics, prognostics, and treatment decision making. 5,6 Within AI, machine learning ...

Advancements in early detection and multimodal treatment strategies have significantly improved survival rates for early-stage breast cancer, now exceeding 80% at 10 years. However, breast cancer ...

Genomic Characterization of Papillary Thyroid Cancer Reveals Germline Mutations Associated With Congenital Hypothyroidism Twenty-five patients were recruited in the study (14 male and 11 female ...

Women are increasingly becoming a significant force in medicine, with their proportion rising from 26% in 2004 to 38% in 2022. 1 This trend extends across all medical subspecialties, with female ...

Patients 65 years and older with previously untreated MCL received acalabrutinib (100 mg twice daily) or placebo (until disease progression or unacceptable toxicity), plus six cycles of bendamustine ...

Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal ...

Background: Both Becotatug (JMT101, humanized IgG1 anti-EGFR monoclonal antibody [mAb]) ± chemotherapy, and Enlonstobart (SG001, humanized IgG4 anti-PD-1 mAb), demonstrated promising antitumor ...

NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.

Background: The standard STUPP regimen (radiotherapy with temozolomide [TMZ] followed by adjuvant TMZ) remains limited in efficacy for newly diagnosed glioblastoma (GBM). Anlotinib, a multi-kinase ...

LBA3515Background: Retreatment (re-tx) with anti-EGFR monoclonal antibodies offers a promising approach to extend the continuum of care of patients (pts) with RAS and BRAF wild-type (wt) metastatic ...

Background: BREAKWATER (NCT04607421) is an open-label, global, randomized, phase 3 study evaluating first-line (1L) encorafenib + cetuximab (EC) ± chemotherapy (chemo) vs standard of care (SOC; chemo ...